Bortezomib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 325-345

  Einsele, Hermann ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

26 S PROTEASOME; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; POMALIDOMIDE; PREDNISONE; PROTEASOME; PROTEIN BCL 2; SALINOSPORAMIDE A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIZATION; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME INHIBITION; EVENT FREE SURVIVAL; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LIMB PAIN; MALAISE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; UBIQUITINATION; VOLUME OF DISTRIBUTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WEAKNESS; ANIMAL; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84905496101     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_20     Document Type: Article

References (161)

1. Adams J, Behnke M, Chen S et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333–338
2. Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622
3. Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505–2511
4. Aghajanian C, Dizon DS, Sabbatini P et al (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943–5949
5. Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89
6. Alexanian R, Dimopoulos MA, Delasalle K et al (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80(4):887–890
7. Alsina M, Trudel S, Vallone M et al (2007) Phase I single agent antitumor activity of twice weekly-consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood 110:128a (abstract 411)
8. Anderson KC (2013) Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw 11(5 Suppl):676–679
9. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe francais du myelome. New Engl J Med 335:91–97
10. Barlogie B, Shaughnessy JD, Tricot G et al (2004) Treatment of multiple myeloma. Blood 103:20–32
11. Belch A, Kouroukis CT, Crump M et al (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18:116–121
12. Bennouna J, Delord JP, Campone M, Pinel M-C (2008) Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14:1610–1617
13. Berenson JR, Yang HH, Sadler K et al (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937–944
14. Biehn SE, Moore DT, Voorhees PM et al (2007) Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86:211–216
15. Bladé J, San Miguel JF, Fontanillas M et al (2001) Increased conventional chemotherapy does not improve survival in multiple myeloma: longterm results of two PETHEMA trials including 914 patients. Hematol J 2:272–278
16. Blaney SM, Bernstein M, Neville K et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children’s Oncology Group study (ADVL0015). J Clin Oncol 22:4804–4809
17. Bowerman B, Kurz T (2006) Degrade to create: developmental requirements for ubiquitinmediated proteolysis during early C. elegans embryogenesis. Development 133:773–784
18. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M (1999) The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1:221–226
19. Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, Tanaka K, Dyson J, Rivett J (2000) Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 346(Pt 1):155–161
20. Cavo M, Benni M, Ronconi S et al (2002) Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 87:934–942
21. Chanan-Khan AA, Padmanabhan S, Miller KC et al (2006) Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rate in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood vol 108, p 1010a
22. Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604–2606
23. Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood 87:1104–1112
24. Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8:407–419
25. Chen CI, Kouroukis CT, White D et al (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570–1575
26. Choy H, Park C, Yao M (2008) Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 14:1618–1623
27. Ciechanover A (2005) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 12:1178–1190
28. Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 22:442–451
29. Cortes J, Thomas D, Koller C et al (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10:3371–3376
30. Cusack JC Jr, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 61:3535–3540
31. Davies FE, Wu P, Srikanth M et al (2006) The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with minimal toxicity compared to velcade alone (V) and velcade plus dexamethasone (VD). In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood vol 108, p 1009a
32. Delic J, Masdehors P, Omura S et al (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-a-initiated apoptosis. Br J Cancer 77:1103–1107
33. Demartino GN, Gillette TG (2007) Proteasomes: machines for all reasons. Cell 129:659–662
34. Demo SD, Kirk CJ, Aujay MA et al (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383–6391
35. Dimopoulos MA, Pouli A, Zervas K et al (2003) Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 14:1039–1044
36. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al (2005) Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica 90:1655–1658
37. Dy GK, Thomas JP, Wilding G et al (2005) A phase and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410–3416
38. Elliott PJ, Zollner TM, Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81:235–245
39. Facon T, Mary JY, Pegourie B et al (2006) Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292–1298
40. Feling RH, Buchanan GO, Mincer TJ et al (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42:355–357
41. Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273:8545–8548
42. Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867–4874
43. Friedman J, Al-Zoubi A, Kaminski M et al (2006) A new model predicting at least a very good partial response in patients with multiple myeloma after cycles of velcade-based therapy. In: Updated data presented at the 2006 annual meeting of the European Hematology Association. Haematologica, vol 91, p 273
44. Fuchs SY (2002) The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 1:337–341
45. Gautschi O, Heighway J, Mack PC et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1624–1633
46. Gertz MA, Lacy MQ, Dispenzieri A et al (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expet Rev Anticancer Ther 6:343–360
47. Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426:895–899
48. Goy A, Younes A, McLaughlin P et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 23:667–675
49. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D (2000) A gated channel into the proteasome core particle. Nat Struct Biol 7:1062–1067
50. Harousseau JL, Mathiot C, Attal M et al (2007) VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood 110:139a
51. Harousseau JL, Mathiot C, Attal M et al (2008) Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 26:455s
52. Hernandez JM, Garcia-Sanz R, Golvano E et al (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127:159–164
53. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
54. Hideshima T, Chauhan D, Podar K et al (2001) Novel therapies targeting the myeloma cell and its bone marrow micro environment. Semin Oncol (6):607–612 (Review)
55. Hideshima T, Chauhan D, Richardson P et al (2002) NF-jB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647
56. Hideshima T, Podar K, Chauhan D et al (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766–8776
57. Hideshima T, Bradner JE, Wong J et al (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567–8572
58. Hideshima T, Catley L, Yasui H et al (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053–4062
59. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim KB (2007) LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 14:419–430
60. Hollmig K, Stover J, Talamo G et al (2004) Bortezomib (VelcadeTM) + AdriamycinTM + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). In: Updated data presented at the 2004 annual meeting of the American Society of Hematology. Blood, vol 104, p 659a
61. Imajoh-Ohmi KT, Sugiyama S, Tanaka K, Omura S, Kikuchi H (1995) Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070–1077
62. Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172
63. Jagannath S, Barlogie B, Berenson JR et al (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103:1195–1200
64. Jagannath S, Richardson PG, Sonneveld P et al (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151–157
65. Jesenberger V, Jentsch S (2002) Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3:112–1121
66. Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16:76–81
67. Knop S, Einsele H, Bargou R et al (2008) Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. Leuk Lymphoma 49(2):346–349
68. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S (1999) A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635–644
69. Kohler A, Cascio P, Leggett DS, Woo KM, Goldberg AL, Finley D (2001) The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell 7:1143–1152
70. Kortuem KM, Stewart AK (2013) Carfilzomib. Blood 121(6):893–897
71. Kropff MH, Bisping G, Wenning D et al (2005a) Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29:587–590
72. Kropff M, Bisping G, Liebisch P et al (2005b) Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. In: Updated data presented at the 2005 annual meeting of the American Society of Hematology. Blood, vol 106, p 716a
73. Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110:3281–3290
74. Kyle RA, Rajkumar SV (2004) Multiple myeloma. New Eng J Med 351:1860–1873
75. Lee JL, Swain SM (2008) The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 14:1643–1649
76. Lee SJ, Richardson PG, Sonneveld P et al (2005) Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): results from APEX study. J Clin Oncol 23:568s
77. Leoni F, Casini C, Breschi C et al (2006) Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. In: Updated data presented at the 2006 annual meeting of the European Hematology Association. Haematologica, vol 91, p 281
78. Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841–849
79. Lonial S, Waller EK, Richardson PG et al (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777–3784
80. Loo TW, Clarke DM (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrateinduced transmembrane domain interactions. J Biol Chem 273:14671–14674
81. Loo TW, Clarke DM (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 7:1724–1732
82. Ma MH, Yang HH, Parker K et al (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 3:1136–1144
83. Ma C, Mandrekar SJ, Alberts SR et al (2007) A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59:207–215
84. Mateos MV, Hernandez JM, Hernandez MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165–2172
85. Mateos MV, Hernandez JM, Hernandez MT et al (2007) Frontline VMP in elderly MM patients: extended follow-up. Haematologica 92:180
86. Messersmith WA, Baker SD, Lassiter L et al (2006) Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270–1275
87. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Biologic sequelae of nuclear factor-jB blockade in multiple myeloma: therapeutic applications. Blood 99:4079–4086
88. Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377–2380
89. Mitsiades CS, Mitsiades NS, McMullan CJ et al (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107:1092–1100
90. Mohrbacher A, Levine AM (2005) Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 23:612s
91. Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, Feng H, Girgis S, Cakana A, van de Velde H, Deraedt W, Facon T (2012) Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 51(12):823–829
92. Muratani M, Tansey WP (2003) How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4:192–201
93. Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842
94. Naujokat C, Hoffmann S (2002) Role and function of the 26 S proteasome in proliferation and apoptosis. Lab Invest 82:965–980
95. Nawrocki ST, Carew JS, Dunner K Jr et al (2005a) Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65:11510–11519
96. Nawrocki ST, Carew JS, Pino MS et al (2005b) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658–11666
97. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21:30–36
98. O’Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non–Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23:676–684
99. Obeng EA, Carlson LM, Gutman DM et al (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907–4916
100. Orlowski RZ, Baldwin AS (2002) NF-jB as a therapeutic target in cancer. Trends Mol Med 8:385–389
101. Orlowski RZ, Eswara JR, Lafond-Walker A et al (1998) Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res 58:4342–4348
102. Orlowski RZ, Small GW, Shi YY (2002a) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277:27864–27871
103. Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002b) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420–4427
104. Orlowski RZ, Kuhn DJ, Small GW, Michaud C, Orlowski M (2005a) Identification of novel inhibitors that specifically target the immunoproteasome, and selectively induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems. Blood 106:76a (abstract 248)
105. Orlowski RZ, Voorhees PM, Garcia RA et al (2005b) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058–3065
106. Orlowski RZ, Zhuang SH, Parekh T et al (2006) DOXIL-MMY-3001 Study Investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood, vol 108, p 124a
107. Orlowski RZ, Stewart K, Vallone M et al (2007) Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase I results. Blood 110:127a (abstract 409)
108. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831
109. Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767–2772
110. Palumbo A, Schlag R, Khuageva N et al (2008) Prolonged therapy with bortezomib plus melphalan–prednisone (VMP) results in improved quality and duration of response in the phase III VISTA study in previously untreated multiple myeloma (MM). Haematologica 93:83
111. Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108–2121
112. Pautasso C, Bringhen S, Cerrato C, Magarotto V, Palumbo A (2013) The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol, 9 Jul 2013 (Epub ahead of print)
113. Popat R, Goff L, Oakervee HE et al (2005) Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma. Blood 106:697a
114. Popat R, Williams C, Cook M et al (2006) A phase I/ II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood, vol 108, p 1011a
115. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630–639
116. Reece DE, Piza G, Trudel S et al (2006) A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood, vol 108, p 1009a
117. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348:2609–2617
118. Richardson P, Sonneveld P, Schuster M et al (2005a) Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma:updated results of the APEX trial. In: Updated data presented at the 2005 annual meeting of the American Society of Hematology. Blood, vol 106, p 715a
119. Richardson PG, Sonneveld P, Schuster MW et al (2005b) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 352:2487–2498
120. Richardson PG, Barlogie B, Berenson J et al (2006a) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106:1316–1319
121. Richardson PG, Briemberg H, Jagannath S et al (2006b) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120
122. Richardson PG, Jagannath S, Avigan DE et al (2006c) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood, vol 108, p 124a
123. Richardson PG, Mitsiades C, Ghobrial I et al (2006d) Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 18:598–608
124. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006e) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33–47
125. Richardson PG, Sonneveld P, Schuster M et al (2007a) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560
126. Richardson PG, Sonneveld P, Schuster MW et al (2007b) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 137:429–435
127. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121(11):1961–1967
128. Rifkin RM, Gregory SA, Mohrbacher A et al (2006) Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 106:848–858
129. Rivett AJ, Hearn AR (2004) Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr Protein Pept Sci 5:153–161
130. Robertson JD, Datta K, Biswal SS, Kehrer JP (1999) Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J 344:477–485
131. Ruiz S, Krupnik Y, Keating M et al (2006) The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 5:1836–1843
132. Ryan DP, O’Neil BH, Supko JG et al (2006) A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107:2688–2697
133. Sagaster V, Ludwig H, Kaufmann H et al (2007) Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21:164–168
134. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Eng J Med 359:906–917
135. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31(4):448–455
136. Schmidt M, Hanna J, Elsasser S, Finley D (2005) Proteasome-associated proteins: regulation of a proteolytic machine. Biol Chem 386:725–737
137. Shi YY, Small GW, Orlowski RZ (2006) Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100:33–47
138. Shinohara K, Tomioka M, Nakano H et al (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385–388
139. Sin N, Kim KB, Elofsson M et al (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9:2283–2288
140. Small GW, Shi YY, Edmund NA et al (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66:1478–1490
141. Sonneveld P, Richardson PG, Schuster MW et al (2005) Bortezomib at first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma. Haematologica 90:146–147
142. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955
143. Stapnes C, Doskeland AP, Hatfield K et al (2007) The proteasome inhibitors bortezomib and PR- 171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136:814–828
144. Strauss SJ, Maharaj L, Hoare S et al (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor a response with clinical activity. J Clin Oncol 24:2105–2212
145. Strickland E, Hakala K, Thomas PJ, DeMartino GN (2000) Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. J Biol Chem 275:5565–5572
146. Suvannasankha A, Smith GG, Juliar BE et al (2006) Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 7:131–134
147. Teicher BA (2008) Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14:1650–1657
148. Teoh G, Tan D, Hwang W et al (2006) Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed/refractory multiple myeloma. In: Updated data presented at the 2006 annual meeting of the American Society of Clinical Oncology. J Clin Oncol, vol 24, p 683s
149. Terpos E, Anagnostopoulos A, Heath D et al (2006) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1-alpha and angiogenic cytokines. In: Updated data presented at the 2006 annual meeting of the American Society of Hematology. Blood, vol 108, pp 1010a–1011a
150. Treon SP, Hunter ZR, Matous J et al (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03–248. Clin Cancer Res 13:3320–3325
151. van de Donk NW, Lokhorst HM (2013) New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother 14(12):1569–1573
152. Vinitsky A, Michaud C, Powers JC, Orlowski M (1992) Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31:9421–9428
153. Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M (1994) Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 269:29860–29866
154. Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316–6325
155. Voorhees PM, Chen Q, Kuhn DJ et al (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13:6469–6478
156. Voortman J, Smit EF, Honeywell R et al (2007) A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 13:3642–3651
157. Wang T (2003) The 26S proteasome system in the signaling pathways of TGF-beta superfamily. Front Biosci 8:d1109–d1127
158. Wang CY, Mayo MW, Baldwin AS Jr (1996) TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kB. Science 274:784–787
159. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB. Nat Med 5:412–417
160. Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P (2006) Efficacy and safety of bortezomib in systemic AL amyloidosis-a preliminary report. Blood 108:42a (abstract 129) Wojcikiewicz RJ (2004) Regulated ubiquitination of proteins in GPCR-initiated signaling pathways. Trends Pharmacol Sci 25:35–41
161. Zangari M, Barlogie B, Burns MJ et al (2005) Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001–37: superior outcome in patients with normal cytogenetics and no prior T. In: Updated data presented at the 2005 Annual Meeting of the American Society of Hematology. Blood, vol 106, p 717.